Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevos medicamentos para el tratamiento de heridas crónicas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOCH20180703001
Publicado:
17/07/2018
Caducidad:
10/07/2019
Resumen:
Una empresa suiza perteneciente al sector de biotecnología ha desarrollado un medicamento que aumenta el flujo local de sangre en una herida y evita el problema de disminución del flujo de sangre, importante en heridas que no cicatrizan. El compuesto en desarrollo tiene un modo de acción único y una eficacia sin precedentes para la cicatrización de heridas. Los estudios preclínicos en células de músculos lisos vasculares y modelos animales han demostrado que la molécula candidata tiene una mayor eficacia y potencia en la angiogénesis que los compuestos o vehículos de referencia. La empresa busca compañías farmacéuticas con el fin de establecer acuerdos de licencia o financiación, así como universidades para alcanzar acuerdos de investigación y realizar una prueba de concepto adicional y validación en estudios animales.

Details

Tittle:
Novel drugs for the treatment of chronic wounds
Summary:
The Swiss biotech company´s priority development drug increases local blood flow in the wound area and addresses impaired blood flow, a central problem in non-healing wounds. The compound under development has a unique mode of action and unprecedented efficacy to enable wound healing. The SME is looking for pharmaceutical corporations for licensing or financial agreements and universities for a research cooperation agreement to bring additional proof of concept and validation in animal studies.
Description:
Diabetes mellitus is one of the major health concerns worldwide affecting 425 million people and its prevalence is expected to increase to 629 million by 2045. It is estimated that 12% of the global health expenditure is spent on diabetes (around $727 billion). One serious complication of diabetes mellitus is the diabetic foot ulcer (DFU). Impaired local blood circulation and the resulting low tissue oxygenation, nutrient supply and waste elimination is a major cause for compromised wound healing in diabetic patients and wounds often become chronic and non-healing. Approximately 15% of all diabetic patients will develop an ulcer in their life time. DFU is the most common reasons for hospitalisation and the most frequent cause of lower extremity amputations (LEAs). In fact, every 20 seconds a lower limb is lost due to diabetes somewhere in the world. In spite of significant improvements with current Standard of Care (SoC) there remains a pressing need for innovative treatments.

The Swiss biotech start-up company is developing therapies for the treatment of severe wounds. Based on preclinical studies on vascular smooth muscle cells, isolated organ studies and animal models, the low molecular weight clinical candidate showed increased efficacy and potency on angiogenesis when compared to reference compounds or vehicles. Therapies based on the drug candidate are expected to provide significant benefit on top of existing treatment options for wound healing and prophylaxis of diabetic foot ulcer. Other applications may include erectile dysfunction, pulmonary hypertension and medical cosmetics.

The partner sought could be a large Pharma concern interested in:
- A license agreement to commercialize the technology
- A research cooperation agreement to launch clinical trials
- A financial agreement to move to the next clinical phases

The company is as well evaluating additional academic research cooperation to strengthen the scientific understanding of the unique mode of action.
Advantages and Innovations:
Drugs improving compromised local endothelial dysfunction, microcirculation and angiogenesis are not approved and commercialised for DFU. The current SoC treatments include:
- Skin substitutes
- Growth factors
- Negative-pressure wound therapy (NPWT)
- Herbal medicine

Despite these achievements, there remains a pressing need for innovative and improved `Medicine that Matters` in DFU targeting key disease mechanisms in this ailment. The elevated number of LEA for DFU underscores the urgency to deliver new drugs with a significant therapeutic advantage when added to SoC.
Therapies based on the new drug are expected to provide significant benefit on top of existing treatment options for wound healing and prophylaxis of diabetic foot ulcers by improving microcirculation and fostering angiogenesis at the wound area.

Stage of Development:
Prototype available for demonstration
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
The specific area of activity of the partner:
Pharmaceutical companies, universities and R-Y-D organisations with expertise in wound healing:

1. R-Y-D in wound healing
2. Good Manufacturing Practise (GMP) production of microparticles
3. Preparation and execution of Clinical Trials
4. Commercialisation of an innovative drug

The tasks to be performed by the partner sought:

1. Development of a slow-release formulation
2. In-vivo studies in wound healing animal model
3. Development of Clinical Trials Phase I and II

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001011 Enfermedades circulatorias y del corazón
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos